Skip to main content
. 2022 Aug 18;6(16):4821–4830. doi: 10.1182/bloodadvances.2022007474

Figure 2.

Figure 2.

Cumulative incidence of proven or probable invasive fungal disease following CD19 CAR T-cell therapy. At 18 months (A) and 100 days (B).